Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Qulipta
Pharma
AbbVie's Ubrelvy fares well warding off migraines in study
In a study published this week in the journal Neurology, AbbVie's Ubrelvy was 73% more effective in preventing a migraine attack than placebo.
Kevin Dunleavy
Aug 29, 2024 11:58am
Pfizer's Vydura gets NICE nod to treat episodic migraine attacks
Sep 13, 2023 7:01pm
Docs very willing to use AbbVie's Qulipta in chronic migraine
Apr 25, 2023 12:46pm
AbbVie's Qulipta gains approval to prevent chronic migraines
Apr 18, 2023 3:20pm
FDA signs off on Pfizer's Zavypret, a nasal spray for migraine
Mar 10, 2023 10:53am
Eli Lilly hit by migraine drug launch slowdown, but rivals jump
Aug 5, 2022 11:58am
